TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01079000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opinion Leader letter
Description: The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opinion Leader letter
Description: The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Involvement of a care manager
Description: The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
Study: NCT03067025

Intervention type: DEVICE
Intervention: Actigraphy
Description: Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).

Intervention type: DEVICE
Intervention: Actigraphy
Description: Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
Study: NCT01079000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care provided to asthma patients when discharged from the ED

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided to asthma patients when discharged from the ED

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care provided to asthma patients when discharged from the ED
Study: NCT04354740

Intervention type: PROCEDURE
Intervention: with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)
Description: II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:

Intervention type: PROCEDURE
Intervention: with percutaneous coronary intervention (PCI) are with new-generation drug-eluting stents (DES)
Description: II-PCI:~-Coronary angiography and intervention will be done according to the European guidelines of ACS revascularization.~III-CABG:
Study: NCT03047512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Internet-based program
Description: * Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~* Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~* Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered.
Study: NCT02530086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube placement
Description: Placement of a Nasogastric tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Nasogastric tube use
Description: No placement of a Nasogastric tube
Study: NCT04518527

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tape
Description: The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tape
Description: The tape is an elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability
Study: NCT00005009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
Study: NCT02263222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-10013
Study: NCT01002417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 15 mg/day
Description: One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 15 mg/day
Description: One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 30 mg/day
Description: Two MCS-2 soft-gel capsules, oral daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS-2 30 mg/day
Description: Two MCS-2 soft-gel capsules, oral daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo soft-gel capsules, oral daily for 12 weeks.
Study: NCT02423200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-745
Description: Orally-active P38 MAP kinase alpha-selective inhibitor
Study: NCT00897507

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02729727

Intervention type: DEVICE
Group type: OTHER
Intervention: CryoBalloon Ablation System
Description: Tissue Ablation using CryoBalloon Ablation System
Study: NCT01631760

Intervention type: GENETIC
Intervention: no intervention
Description: We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.

Intervention type: GENETIC
Intervention: no intervention
Description: We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.

Intervention type: GENETIC
Intervention: no intervention
Description: We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
Study: NCT01834625

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan

Intervention type: DIAGNOSTIC_TEST
Intervention: PET scan
Study: NCT04057729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: 10mg/capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: 10mg/capsule.
Study: NCT03572686

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine 0.5% 20mL
Description: In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.25% 20ml
Description: In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% 20ml + dexamethasone 8mg
Description: In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
Study: NCT01214655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study: NCT04282109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Paclitaxel
Description: Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Paclitaxel
Description: Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months.
Study: NCT00278473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meta-Cognitive Therapy
Description: Cognitive Behavioral Group Treatment
Study: NCT01012895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks
Study: NCT02690350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1784
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Study: NCT01012895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 600 mg, twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 600 mg, twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200mg, twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200mg, twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200mg, twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks
Study: NCT00278473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Social Support Problem-Solving Group Treatment
Study: NCT02224794

Intervention type: DEVICE
Intervention: Ovation® Abdominal Stent Graft Platform

Intervention type: DEVICE
Intervention: Ovation® Abdominal Stent Graft Platform

Intervention type: DEVICE
Intervention: Ovation® Abdominal Stent Graft Platform
Study: NCT02690350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1784
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1784
Description: Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
Study: NCT04649437

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quantitative sensory testing
Description: Quantitative sensory testing recordings will be collected by pressure algometry Assessment of temporal summation of pressure pain and conditioning pain modulation will be used to investigate the involvement of pain sensitization.
Study: NCT00352664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
Study: NCT04707833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological testing for COVID-19 infection
Description: The tests used will be the following:~EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)
Study: NCT03161652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DR vitrectomy lactose pill
Description: Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR vitrectomy levosulpiride
Description: Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
Study: NCT00403611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel 60 mg/kg
Description: Praziquantel (Distocide) 60 mg/kg single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Praziquantel 40 mg/kg
Description: Praziquantel (Distocide) 40 mg/kg single oral dose
Study: NCT03039686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239361
Description: Take RO7239361 subcutaneously on specified days over a 48 week blinded period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239361
Description: Take RO7239361 subcutaneously on specified days over a 48 week blinded period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RO7239361
Description: Take placebo subcutaneously on specified days over a 48 week blinded period
Study: NCT02246244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01845194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: Treatment period 2:~5 mg Codeine once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Treatment period 2:~5 mg Pravastatin once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talinolol
Description: Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Treatment period 1:~50 mg Caffeine 3x

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Treatment period 1:~5 mg Metoprolol 3x
Study: NCT02393404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT-FMT
Description: Physiotherapeutic functional movement-power training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT alone
Description: Physiotherapeutic power training
Study: NCT02894541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-519 200mg
Study: NCT01958502

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold
Study: NCT03343002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl at 10-15 min before end of surgery
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl at end of surgery
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Study: NCT03582098

Intervention type: DRUG
Intervention: Idelalisib
Description: Tablets were administered in accordance with the marketing authorization.

Intervention type: DRUG
Intervention: Rituximab
Description: Tablets were administered in accordance with the marketing authorization.
Study: NCT04328168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROM exercises, stretching, positioning, gait training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: by two physiotherapist under the supervision of a doctor
Study: NCT02676232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DARWeb
Description: Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
Study: NCT02112617

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
Study: NCT01482442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIR-Sphere
Description: The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
Study: NCT03611920

Intervention type: PROCEDURE
Intervention: Tetracycline
Description: Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation

Intervention type: PROCEDURE
Intervention: Dexamethasone
Description: Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation